Fatigue in chronically ill patients

Current Opinion in Supportive and Palliative Care

Volumn 2, Issue 3, 2008, Pages 180-186

  Harris, Juan Diego ^a,b,c  

^a Richard E Winter Cancer Treatment Center   (United States)

^b Claxton Hepburn Medical Center   (United States)

^c St Lawrence Health Alliance   (United States)

Author keywords

Cancer; Chronic illness; Fatigue; Methylphenidate; Palliative care

Indexed keywords

CHRONIC DISEASE; FATIGUE; HUMAN; KINESIOTHERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT EDUCATION; REVIEW;

CHRONIC DISEASE; EXERCISE THERAPY; FATIGUE; HUMANS; PALLIATIVE CARE; PATIENT EDUCATION AS TOPIC;

EID: 54049148656     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32830baed0     Document Type: Article

References (63)

1. Teunissen S, Wesker W, Kruitwagen C, etal. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94-104.
2. Radbruch L, Strasser F, Elsner F, etal. Fatigue in palliative care patients - an EAPC approach. Palliative Medicine 2008; 22:13-22.
3. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 1997; 34:4-12.
4. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92 (suppl 6):1684-1688.
5. Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 2002; 12:424-428.
6. Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer- related fatigue. JNCCN 2007; 5:1081 -1091.
7. Mock V, Abernethy AP, Atkinson A, et al. The Complete Library of NCCN Clinical Practice Guidelines in Oncology. Cancer-related fatigue. (CD ROM,June 2007).
8. Hann DM, Jacobsen PB, Azzarello LM, etal. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 1998; 7:301-310.
9. MendozaTR, Wang XS, Cleeland CS, etal. The rapid assessment of fatigue in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85:1186-1196.
10. Piper BF, Dibble SL, Dodd MJ, et al. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 1998; 25:677-684.
11. Smets EM, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39:315-325.
12. Franklin DJ, Packel L. Cancer-related fatigue. Arch Phys Med Rehabil 2006; 87 (3 Suppl 1):S91 -S93.
13. Schmitz KH, Holtzman J, Courneya KS, et al. Controlled physical activitytrials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14:1588-1595.
14. Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer InstMonogr 2004; 32:112-195.
15. White LJ, McCoy SC, Castellano V, et al. Resistance training improves strengthandfunctionalcapacityinpersonswithmultiplesclerosis.MultScler 2004; 10:668-674.
16. Wagner LI, Della D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004; 91:822-828.
17. Jacobsen PB, Meade CD, Stein KD, et al. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol 2002; 20:2851-2862.
18. Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer 2000; 8:385-397.
19. Candy B, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008:CD006722.
20. Sood A, Barton DL, Loprinzi CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006; 23:35-40.
21. Bruera E, Valero V, Driver LC, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24:2073-2078.
22. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double- blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161:411-420.
23. Sarhill N, Walsh D, Nelson KA, etal. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care 2001; 18:187-192.
24. Sugara Y, Akechi T, Shima Y, et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002; 16:261 -263.
25. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002; 29:E85-E90.
26. Bruera E, Driver LC, Barnes EA, etal. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21:4439-4443.
27. Hanna A, Sledge G, Mayer ML, etal. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006; 14:210-215.
28. Bruera E, El Osta B, Valero V, Driver LC, etal. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2007;24:3475-3481.
29. Minton O, Stone P, Richardson A, et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008:CD006704.
30. Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006; 2:130-136.
31. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135-140.
32. Mitler MM, Harsh J, Hirshkowitz M, et al. Long-term efficacy and safety of modafinil (Provigil®)for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000; 1:231-243.
33. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS. A randomized placebo-controlled double-blind study. Neurology 2005;64:1139-1143.
34. Morrow GR, Gillies LJ, Hickok JT, et al. The positive effect of the psycho- stimulant modafinil on fatigue from cancer that persists after treatment is completed [abstract #8012]. J Clin Oncol 2005; (Suppl 16):732s.
35. Slatkin NE, Rhiner M. Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. J Support Oncol 2003; 1:53-63.
36. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003; 26:1049-1054.
37. Ettinger AB, Portenoy RK. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 1988; 3:99-103.
38. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994; 9:442-445.
39. Vaccarino AL, Couret LC Jr. Relationship between hypothalamic-pituitary- adrenal activity and blockade of tolerance to morphine analgesia by pain: a strain comparison. Pain 1995; 63:385-389.
40. Harris JD, Kotob F. Management of opioid-related side effects. In: de Leon- Casasola OA, editor. Cancer Pain: Pharmacological, Interventional, and Palliative Care. Philadelphia: Elsevier Inc; 2006. pp. 207-230.
41. Strasser F, Palmer JL, Schover LR, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function and sexual desire in male patients with advanced cancer: a pilot study. Cancer 2006; 107:2949-2957.
42. Shafqat A, Einhorn LH, Hanna N, et al. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 2005; 16:1545-1550.
43. Del Fabbro E, Dalal S, Bruera E. Symptom control in palliative care - part II: cachexia/anorexia and fatigue. J Palliat Med 2006; 9:409-421.
44. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004;49:139-144.
45. Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects ofbupropion SR on fatigue, depression and quality oflife ofmixed-site cancer patients and their partners. Psychooncology 2006; 15:259-267.
46. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and metaanalysis of controlled clinical trials. J Natl Cancer Inst 2001; 93:1204-1214.
47. Munch TN, Zhang T, Willey J, et al. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J PalliatMed 2005; 8:1144-1149.
48. Henke M, Laszig R, Rube C, etal. Erythropoietin to treat head and neckcancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
49. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-460.
50. Wun T, Law L, Harvey D, et al. Increased incidence ofsymptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation and erythropoietin. Cancer 2003; 98:1514-1520.
51. Rosenzweig MQ, Bender CM, Lucke JP, et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27:185-190.
52. Brower V. Epoietin for cancer patients: a boon or a danger? J Natl Cancer Inst 2003; 95:1820-1821.
53. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92:1684-1688.
54. Moreland LW, Genovese MC, Sato R, Singh A. Effectofetanercepton fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006; 55:287-293.
55. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29-35.
56. Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al. Study of eta- nercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005; 23:5950-5959.
57. Madhusudan S, Foster M, Muthuramalingam SR. A phase II study of etaner- cept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with meta- static breast cancer. Clin Cancer Res 2004; 10:6528-6534.
58. Gordon JN, Trebble TM, Ellis RD, etal. Thalidomide in the treatmentofcancer cachexia: a randomised placebo controlled trial. Gut 2005; 54:540-545.
59. Khan ZH, Simpson EJ, Cole AT. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther 2003; 17:677 -682.
60. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage 2006; 32:551-559.
61. Gramignano G, Lusso MR, Madeddu C, etal. Efficacy of L-carnitine administration on fatigue, nutritional status, oxidative stress, and related qualityoflife in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 2006; 22:136-145.
62. Cruciani RA, Dvorkin E, Homel P, et al. L-Carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann NY Acad Sci 2004; 1033:168-176.
63. Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non- anaemic cancer patients. Br J Cancer 2002; 86:1854-1857.